Harrow has successfully leveraged its compounding ... In fact, I suspect many investors do not yet know that this data is no longer of use, and may be surprised by the actual data that HROW ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ('Formosa', 6838.TW), today announced a licensing agreement, whereby Harrow has ...

"Following Harrow’s investment in the restoration of ... off-label options they had been forced to use while TRIESENCE was unavailable. This news, which allows for the reimbursement of TRIESENCE ...